Alnylam Pharmaceuticals, Inc. (BMV:ALNY)

Market Cap	696.32B -1.5%
Revenue (ttm)	77.28B +82.6%
Net Income	9.70B
EPS	71.21
Shares Out	n/a
PE Ratio	71.80
Forward PE	26.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8
Average Volume	325
Open	5,420.00
Previous Close	8,380.00
Day's Range	5,420.00 - 5,420.00
52-Week Range	5,420.00 - 8,560.00
Beta	n/a
RSI	54.42
Earnings Date	Apr 30, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 2,500
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ALNY

Financial Performance

Financial numbers in USD